3-[(氯甲基)二甲基硅基]-1-丙醇 | 18171-24-9

• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 中文名称: 3-[(氯甲基)二甲基硅基]-1-丙醇
• 英文名称: dimethyl(chloromethyl)(3-hydroxypropyl)silane
• 英文别名: 3-(chloromethyldimethylsilanyl)propan-1-ol；3-(chloromethyl-dimethyl-silanyl)-propan-1-ol；3-[(chloromethyl)dimethylsilyl]propanol；chloromethyldimethylsilyl 3-propanol；chloromethyldimethylsilyl-3-propanol；γ-Hydroxypropyl-chlormethyl-dimethyl-silan；1-Propanol, 3-[(chloromethyl)dimethylsilyl]-；3-[chloromethyl(dimethyl)silyl]propan-1-ol
• CAS: 18171-24-9
• 化学式: C₆H₁₅ClOSi
• mdl: MFCD19232249
• 分子量: 166.723
• InChiKey: DGFRHWIVWJKUIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.26
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-[(氯甲基)二甲基硅基]-1-丙醇 在 lithium aluminium tetrahydride 、 potassium acetate 作用下， 生成 Hydroxymethyl-(3-hydroxy-propyl)-dimethyl-silan-dicarbamat
  参考文献：
  名称：

  硅取代的药物。硅酸氨基甲酸酯与丙氨酯有关。

  摘要：

  DOI：

  10.1021/jm00329a012
• 作为产物：
  描述：

  (氯甲基)(二甲基){3-[(三甲基甲硅烷基)氧代]丙基}硅烷 在 盐酸 、 水 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以2 g的产率得到3-[(氯甲基)二甲基硅基]-1-丙醇
  参考文献：
  名称：

  Synthesis and conformational analysis of 1,3-azasilinanes

  摘要：

  1-Isopropyl-3-methyl-3-phenyl-1,3-azasilinane 1 and 1-isopropyl-3,3-dimethyl-1,3-azasilinane 2 were synthesized and a detailed analysis of their NMR spectra, conformational equilibria and ring inversion processes is presented. Low temperature H-1/C-13 NMR spectroscopy, iteration of the H-1 NMR spectra and quantum chemical calculations showed slight predominance of the PheqMeax over the PhaxMeeq conformer of 1 at low temperature. The barrier for the chair to chair interconversion of both compounds was measured to be 8.25 kcal/mol. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.05.106

文献信息

• C7- substituted camptothecin analogs
  申请人：Narkunan Kesavaram

  公开号：US20090099224A1

  公开（公告）日：2009-04-16

  The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

  本发明的C7修饰的紫杉醇类似物及其药用盐具有以下特点：(i) 在体外对人类和动物肿瘤细胞的生长具有强大的抗肿瘤活性（即在纳摩尔或亚纳摩尔浓度下）；(ii) 对拓扑异构酶I有强大的抑制作用；(iii) 不易受到MDR/MRP药物耐药性的影响；(iv) 无需代谢激活；(v) 不发生A环或B环的葡萄糖醛酸化；(vi) 减少药物与血浆蛋白的结合亲和力；(vii) 保持内酯稳定性；(viii) 保持药效；以及(ix) 具有较低的分子量（例如，分子量<600）。
• [EN] C7-SUBSTITUTED CAMPTOTHECIN ANALOGS<br/>[FR] ANALOGUES DE CAMPTOTHÉCINE SUBSTITUÉS EN C7
  申请人：BIONUMERIK PHARMACEUTICALS INC

  公开号：WO2009051580A1

  公开（公告）日：2009-04-23

  The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B- ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

  本发明的C7-修饰紫杉醇类似物及其药用盐具有以下特点：(i) 在体外对人类和动物肿瘤细胞的生长具有强大的抗肿瘤活性（即在纳摩尔或亚纳摩尔浓度下）；(ii) 对拓扑异构酶I有强大的抑制作用；(iii) 不易受到MDR/MRP药物耐药性的影响；(iv) 无需代谢激活；(v) 不发生A环或B环的葡萄糖醛酸化；(vi) 减少药物与血浆蛋白的结合亲和力；(vii) 保持内酯的稳定性；(viii) 保持药物的效力；以及(ix) 具有较低的分子量（例如，分子量<600）。
• Rearrangements of α-halosilanes induced by intramolecular nucleophilic attack at silicon
  作者：Paul F. Hudrlik、Yousef M. Abdallah、Anne M. Hudrlik

  DOI：10.1016/s0040-4039(00)61765-3

  日期：1992.11

  Migrations of organic groups from silicon to carbon are facilitated by intramolecular attack by alkoxide at silicon.

  有机基团从硅向碳的迁移通过硅的醇盐的分子内攻击而促进。
• Synthesis of l-ascorbic acid derivatives as potential bone remodeling agents taking advantage of the Mitsunobu reaction
  作者：Gil Vilaça、Cyril Rubio、Jacques Susperregui、Laurent Latxague、Gérard Déléris

  DOI：10.1016/s0040-4020(02)01185-7

  日期：2002.11

  The synthesis of ascorbic acid derivatives 7a–d is described. Starting from alkenylacetates 1a–d subjected to a hydrosilylation reaction, the resulting hydroxy chloro silanes 3a–d were obtained in high yield. The latter compounds were reacted with potassium phthalimide followed with hydrazine hydrate to give the amino silanols 5a–d. Ascorbic acid was then alkylated on its 3-hydroxy position to give

  描述了抗坏血酸衍生物7a - d的合成。从进行氢化硅烷化反应的乙酸烯基酯1a – d开始，可以高收率获得生成的羟基氯硅烷3a – d。后面的化合物与邻苯二甲酰亚胺钾反应，然后与水合肼反应，得到氨基硅烷醇5a - d。然后通过Mitsunobu反应将抗坏血酸的3-羟基位置烷基化，得到7a - d。
• Benzamide derivatives
  申请人：RHONE POULENC RORER LIMITED

  公开号：EP0501822A1

  公开（公告）日：1992-09-02

  Benzamide derivatives of the formula : wherein R¹ is optionally substituted alkyl optionally containing double or triple bonds or cycloalkyl rings, which is interrupted by silicon, and optionally interrupted by a hetero atom, and/or by sulphinyl or sulphonyl groups, R² is hydrogen, alkyl, or optionally substituted phenyl or the two groups R² form a 3 to 8-membered ring, R³ is hydrogen or alkyl, R⁴ is alkoxy, alkylthio or dimethylamino, and R⁵ is a group -NR⁸R⁹ or -OR¹⁰ wherein R⁸ and R⁹ each represents hydrogen or alkyl optionally interrupted by a hetero atom, sulphinyl or sulphonyl group and optionally containing one or more carbon-carbon double or triple bonds, and R¹⁰ is alkyl optionally interrupted by a hetero atom, sulphinyl or sulphonyl group, and optionally containing double or triple bonds, or a pharmaceutically acceptable salt thereof, possess useful pharmacological properties.

  苯甲酰胺衍生物的化学式：其中R¹是可选择取代的烷基，可含有双键或三键或环烷基环，由硅断裂，可由杂原子、亚砜基或磺酰基中断，R²是氢、烷基或可选择取代的苯基或两个基团R²形成3到8元环，R³是氢或烷基，R⁴是烷氧基、烷硫基或二甲氨基，R⁵是一个基团-NR⁸R⁹或-OR¹⁰，其中R⁸和R⁹分别表示氢或烷基，可由杂原子、亚砜基或磺酰基中断，可含有一个或多个碳-碳双键或三键，R¹⁰是烷基，可由杂原子、亚砜基或磺酰基中断，可含有双键或三键，或其药用盐，具有有用的药理学性能。